In this week’s EuroBiotech report, the European Investment Bank is using some of its €24 billion ($33 billion) fund to back drug development, Parisian biotech Cellectis is setting up shop in the U.S. after striking a deal worth up to $2.8 billion with Pfizer, and more.

…read more

Source: EU opens €24B fund to biopharma R&D, Cardio3 lands Asian investment, U.K. IPOs heat up


0 No comments